WGS
GeneDx Holdings Corp. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | -5 | 15.43M | $1.06B | +10 | −14 |
| Q1 2026 | 95 | +2 | 15.21M | $977.50M | +14 | −13 |
| Q4 2025 | 94 | +1 | 15.07M | $1.96B | +3 | −1 |
| Q3 2025 | 16 | -1 | 7.41M | $798.15M | +2 | −4 |
| Q2 2025 | 15 | -1 | 4.67M | $430.80M | +1 | −2 |
| Q1 2025 | 13 | 0 | 2.11M | $186.46M | — | — |
| Q4 2024 | 13 | +1 | 1.90M | $146.41M | +2 | −1 |
| Q3 2024 | 11 | +4 | 1.69M | $71.81M | +4 | — |
| Q2 2024 | 7 | — | 992.14K | $25.94M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 347.25K | — | $9.08M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 311.40K | — | $8.14M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 156.75K | — | $4.10M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 90.37K | — | $2.36M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 47.17K | — | $1.23M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 39.18K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 13 | — | $340 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 31.22M shares, $1.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.04K sh · $300,846
Officer · 1.08K sh · $106,816
Officer, Director · 1.65K sh · $155,337
Officer, Director · 148 sh · $14,120
Officer, Director · 1.52K sh · $147,774
Officer, Director · 4.14K sh · $406,936
Officer · 586 sh · $55,235
Officer · 52 sh · $4,961
Officer · 541 sh · $52,423
Officer · 1.47K sh · $144,457
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
1.8% of class · View original SEC filing ↗